|
Market Report
|
Fibromyalgia - Approvals legitimize condition and expose underserved patient population
With a considerable patient potential and large medical unmet need, the untapped fibromyalgia market represents a lucrative opportunity for pharmaceutical companies. Estimated to total around $650m in 2007 in the seven major markets, Datamonitor forecasts the market to grow to over $2.4 billion in 2017.
|
|
Read more...
|
|
|
Market Report
|
Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of market prospects for biologics expose an opportunity for cell and gene therapies
At the forefront of novel technologies; momentum is steadily building for the development of stem cell products to address cardiovascular disease. The most active areas are those with high clinical unmet need heart failure, cardiomyopathy and ishemic heart disease.
|
|
Read more...
|
|
|
Company Report
|
Schering-Plough Corporation: PharmaVitae Profile
This analysis examines the historical and forecast performance for Schering-Plough in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
|
|
Read more...
|
|
|
Market Report
|
Diagnostics in Neurology - Predictive biomarkers expand drug revenues
As advances in omics technologies enable the development of high value molecular diagnostics, neurological conditions represent an attractive target for diagnostic companies. In this report, Datamonitor identifies the diseases in which early detection with a biomarker could significantly benefit the patient, gain payer approval, and ultimately expand the pharmaceutical market.
|
|
Read more...
|
|
|
Product Report
|
Insulin antidiabetics - Return to injections alternative delivery methods fall by the wayside
Alternative delivery methods under development have so far failed to live up to expectations. In many cases the technical difficulties associated with the delivery technique have not been overcome, leading to a return to injection based therapies. Big Pharma have all but exited the development of new insulin therapies leaving the field to small niche players.
|
|
Read more...
|
|
|
Market Report
|
Optimizing Brand Lifecycle Management: Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition
As competitive pressures from the entry of generics post-patent expiry and new brands are growing, product lifecycles are evolving for the worst. Effective lifecycle management is becoming a must for Pharma looking to maximize their return on investment, regardless of which stage of the lifecycle a drugs is in. However such strategies are becoming most prominent immediately before patent expiry.
|
|
Read more...
|
|
|
Company Report
|
Amgen Inc.: PharmaVitae Profile
This analysis examines the historical and forecast performance for Amgen in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
|
|
Read more...
|
|
|
Company Report
|
Novo Nordisk A/S: PharmaVitae Profile
This analysis examines the historical and forecast performance for Novo Nordisk in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
|
|
Read more...
|
|
|
Company Report
|
Bristol-Myers Squibb Co.: PharmaVitae Profile
This analysis examines the historical and forecast performance for BMS in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
|
|
Read more...
|
|
|
Market Report
|
Cytotoxic Therapy Cancer Brands - Looming patent expiries limit market growth
Cytotoxic therapies are the second largest class of cancer therapeutics, generating branded drug sales of over $10 billion in the seven major pharmaceutical markets in 2007. Patent expiries for a number of agents that have achieved blockbuster sales over the years, means that the market continues to attract a considerable amount of generic competition.
|
|
Read more...
|
|
|
Market Report
|
Targeted Therapy Cancer Brands - High growth market will see eight new blockbusters by 2017
Targeted therapies are the top selling class of cancer drug, reaching sales of nearly $15 billion in the seven major pharmaceutical markets in 2007. The high growth of this therapy class makes it attractive to drug developers, resulting in 10 new entrants to the market since 2005. More drugs are likely to gain approval in the near future, contributing to a rapidly changing competitive landscape.
|
|
Read more...
|
|
|
Market Report
|
Cancer Overview - Lung, Brain, Head and Neck, Thyroid
In 2008, the six tumor types covered in this report are forecast to account for over 666,000 new cases of cancer, obviously representing an enormous market potential. However, it is the higher-incidence tumor types that continue to attract drug developers, with lower-incidence cancers potentially suffering due to unfulfilled unmet needs via a lack of R&D activity.
|
|
Read more...
|
|
|
Market Report
|
Antihypertensives: Key patent expiries prevent market growth
Datamonitor expects the antihypertensives market to reach $37 billion, across the seven major markets, by 2017. The growth will be driven by the uptake of Novartis's Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizer's Norvasc and Merck's Cozaar, will restrain market growth.
|
|
Read more...
|
|
|
Company Report
|
Pfizer Inc.: PharmaVitae Profile
This analysis examines the historical and forecast performance for Pfizer in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
|
|
Read more...
|
|
|
Market Report
|
Asthma/COPD - Little long-term future for long-acting single-agent inhalers?
The respiratory market will continue to grow with the same rate over the next few years, with a slight dip between 2012 and 2015 due to the patent expiries of leading products. Growth is driven by the expansion of sales in existing classes, the launch of major new products with safety and convenience advantages, and the results of several landmark trials.
|
|
Read more...
|
|
|
Company Report
|
Genentech Inc.: PharmaVitae Profile
This analysis examines the historical and forecast performance for Genentech in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
|
|
Read more...
|
|
|
Company Report
|
Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile
This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
|
|
Read more...
|
|
|
Company Report
|
Boehringer Ingelheim GmbH: PharmaVitae Profile
This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical sector. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
|
|
Read more...
|
|
Farmavita.Net Journal 
